All In Biotech

Drug Trial Radar · NCT07241546

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Dec 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Conditions

  • Asthma

Interventions

  • ARO-RAGEDrug

    Inhalation of nebulized solution

  • PlaceboDrug

    Calculated volume to match active treatment by inhalation of nebulized solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline Over Time in Maximum Area of ReactanceTime frame: Baseline through Day 58

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 2

    Calgary, Canada · Recruiting

  • Research Site 3

    Edmonton, Canada · Recruiting

  • Research Site 5

    Hamilton, Canada · Recruiting

  • Research Site 6

    Québec, Canada · Recruiting

  • Research Site 4

    Saskatoon, Canada · Recruiting

  • Research Site 1

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.